

WELLS FARGO & COMPANY/MN  
Form 424B2  
February 06, 2017

Filed Pursuant to Rule 424(b)(2)  
File No. 333-202840

**The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement and the accompanying product supplement, market measure supplement, prospectus supplement and prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.**

Subject To Completion, dated February 6, 2017

PRICING SUPPLEMENT No. 823 dated February , 2017

(To Product Supplement No. 4 dated March 18, 2015,

Market Measure Supplement dated March 18, 2015,

Prospectus Supplement dated March 18, 2015

and Prospectus dated March 18, 2015)

## **Wells Fargo & Company**

### **Medium-Term Notes, Series K**

#### **ETF Linked Securities**

#### **Market Linked Securities Leveraged Upside Participation**

#### **and Contingent Downside**

#### **Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

#### **March 7, 2022**

Linked to the Health Care Select Sector SPDR® Fund

Unlike ordinary debt securities, the securities do not pay interest or repay a fixed amount of principal at maturity. Instead, the securities provide for a payment at maturity that may be greater than, equal to or less than the original offering price of the securities, depending on the performance of the Fund from its starting price to its ending price. The payment at maturity will reflect the following terms:

If the value of the Fund increases, you will receive the original offering price plus 115% to 125% (to be determined on the pricing date) participation in the upside performance of the Fund

If the value of the Fund decreases but the decrease is not more than 20%, you will be repaid the original offering price

If the value of the Fund decreases by more than 20%, you will have full downside exposure to the decrease in the value of the Fund from the starting price, and you will lose more than 20%, and possibly all, of the original offering price of your securities

Investors may lose some, or all, of the original offering price

All payments on the securities are subject to the credit risk of Wells Fargo & Company, and you will have no ability to pursue the shares of the Fund or any securities held by the Fund for payment; if Wells Fargo & Company defaults on its obligations, you could lose some or all of your investment

No periodic interest payments or dividends

No exchange listing; designed to be held to maturity

**On the date of this preliminary pricing supplement, the estimated value of the securities is approximately \$932.68 per security. While the estimated value of the securities on the pricing date may differ from the estimated value set forth above, we do not expect it to differ significantly absent a material change in market conditions or other relevant factors. In no event will the estimated value of the securities on the pricing date be less than \$917.00 per security. The estimated value of the securities was determined for us by Wells Fargo Securities, LLC using its proprietary pricing models. It is not an indication of actual profit to us or to Wells Fargo Securities, LLC or any of our other affiliates, nor is it an indication of the price, if any, at which Wells Fargo Securities, LLC or any other person may be willing to buy the securities from you at any time after issuance. See Investment Description in this pricing supplement.**

**The securities have complex features and investing in the securities involves risks not associated with an investment in conventional debt securities. See Selected Risk Considerations herein on page PRS-9 and Risk Factors in the accompanying product supplement.**

**The securities are unsecured obligations of Wells Fargo & Company and all payments on the securities are subject to the credit risk of Wells Fargo & Company. The securities are not deposits or other obligations of a depository institution and are not insured by the Federal Deposit Insurance Corporation, the Deposit Insurance Fund or any other governmental agency of the United States or any other jurisdiction.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this pricing supplement or the accompanying product supplement, market measure supplement, prospectus supplement and prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

|                     | <b>Original Offering Price</b> | <b>Agent Discount<sup>(1)</sup></b> | <b>Proceeds to Wells Fargo</b> |
|---------------------|--------------------------------|-------------------------------------|--------------------------------|
| <b>Per Security</b> | \$1,000.00                     | \$26.20                             | \$973.80                       |
| <b>Total</b>        |                                |                                     |                                |

<sup>(1)</sup> Wells Fargo Securities, LLC, a wholly owned subsidiary of Wells Fargo & Company, is the agent for the distribution of the securities and is acting as principal. See Investment Description in this pricing supplement for further information.

**Wells Fargo Securities**

---

**Market Linked Securities Leveraged Upside Participation and**

**Contingent Downside**

**Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

**March 7, 2022**

**Investment Description**

The Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due March 7, 2022 are senior unsecured debt securities of Wells Fargo & Company that do not pay interest or repay a fixed amount of principal at maturity. Instead, the securities provide for a payment at maturity that may be greater than, equal to or less than the original offering price of the securities depending on the performance of the Health Care Select Sector SPDR® Fund (the Fund ) from its starting price to its ending price. The securities provide:

- (i) the possibility of a leveraged return at maturity if the value of the Fund increases from its starting price to its ending price;
- (ii) repayment of principal if, **and only if**, the ending price of the Fund is not less than the starting price by more than 20%; and
- (iii) full exposure to the decrease in the value of the Fund from the starting price if the ending price is less than the starting price by more than 20%.

**If the ending price is less than the starting price by more than 20%, you will lose more than 20%, and possibly all, of the original offering price of your securities at maturity.** All payments on the securities are subject to the credit risk of Wells Fargo.

The Fund is an exchange traded fund that seeks to track the Health Care Select Sector Index, an equity index that is intended to provide investors with a way to track the movements of certain public companies that represent the health care sector of the S&P 500® Index.

You should read this pricing supplement together with product supplement no. 4 dated March 18, 2015, the market measure supplement dated March 18, 2015, the prospectus supplement dated March 18, 2015 and the prospectus dated March 18, 2015 for additional information about the securities. Information included in this pricing supplement supersedes information in the product supplement, market measure supplement, prospectus supplement and prospectus to the extent it is different from that information. Certain defined terms used but not defined herein have the meanings set forth in the product supplement.

You may access the product supplement, market measure supplement, prospectus supplement and prospectus on the SEC website [www.sec.gov](http://www.sec.gov) as follows (or if such address has changed, by reviewing our filing for the relevant date on the SEC website):

Edgar Filing: WELLS FARGO & COMPANY/MN - Form 424B2

Product Supplement No. 4 dated March 18, 2015 filed with the SEC on March 18, 2015:  
<http://www.sec.gov/Archives/edgar/data/72971/000119312515096527/d890791d424b2.htm>

Market Measure Supplement dated March 18, 2015 filed with the SEC on March 18, 2015:  
<http://www.sec.gov/Archives/edgar/data/72971/000119312515096591/d890724d424b2.htm>

Prospectus Supplement dated March 18, 2015 and Prospectus dated March 18, 2015 filed with the SEC on March 18, 2015:  
<http://www.sec.gov/Archives/edgar/data/72971/000119312515096449/d890684d424b2.htm>

SPDR<sup>®</sup>, S&P 500<sup>®</sup> and Select Sector SPDRs<sup>®</sup> are trademarks of Standard & Poor's Financial Services LLC ( S&P Financial ). The securities are not sponsored, endorsed, sold or promoted by the Select Sector SPDR Trust (the SPDR Trust ), SSgA Funds Management, Inc. ( SSgA ) or S&P Financial. None of the SPDR Trust, SSgA or S&P Financial makes any representations or warranties to the holders of the securities or any member of the public regarding the advisability of investing in the securities. None of the SPDR Trust, SSgA or S&P Financial will have any obligation or liability in connection with the registration, operation, marketing, trading or sale of the securities or in connection with Wells Fargo & Company's use of information about the Health Care Select Sector SPDR<sup>®</sup> Fund.

PRS-2

---

**Market Linked Securities Leveraged Upside Participation and**

**Contingent Downside**

**Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

**March 7, 2022**

**Investment Description (Continued)**

The original offering price of each security of \$1,000 includes certain costs that are borne by you. Because of these costs, the estimated value of the securities on the pricing date will be less than the original offering price. The costs included in the original offering price relate to selling, structuring, hedging and issuing the securities, as well as to our funding considerations for debt of this type.

The costs related to selling, structuring, hedging and issuing the securities include (i) the agent discount, (ii) the projected profit that our hedge counterparty (which may be one of our affiliates) expects to realize for assuming risks inherent in hedging our obligations under the securities and (iii) hedging and other costs relating to the offering of the securities.

Our funding considerations take into account the higher issuance, operational and ongoing management costs of market-linked debt such as the securities as compared to our conventional debt of the same maturity, as well as our liquidity needs and preferences. Our funding considerations are reflected in the fact that we determine the economic terms of the securities based on an assumed funding rate that is generally lower than the interest rates implied by secondary market prices for our debt obligations and/or by other traded instruments referencing our debt obligations, which we refer to as our secondary market rates. As discussed below, our secondary market rates are used in determining the estimated value of the securities.

If the costs relating to selling, structuring, hedging and issuing the securities were lower, or if the assumed funding rate we use to determine the economic terms of the securities were higher, the economic terms of the securities would be more favorable to you and the estimated value would be higher. The estimated value of the securities as of the pricing date will be set forth in the final pricing supplement.

*Determining the estimated value*

Our affiliate, Wells Fargo Securities, LLC (WFS), calculated the estimated value of the securities set forth on the cover page of this pricing supplement based on its proprietary pricing models. Based on these pricing models and related market inputs and assumptions referred to in this section below, WFS determined an estimated value for the securities by estimating the value of the combination of hypothetical financial instruments that would replicate the payout on the securities, which combination consists of a non-interest bearing, fixed-income bond (the debt component) and one or more derivative instruments underlying the economic terms of the securities (the derivative component).

The estimated value of the debt component is based on a reference interest rate, determined by WFS as of a recent date, that generally tracks our secondary market rates. Because WFS does not continuously calculate our reference interest rate, the reference interest rate used in the calculation of the estimated value of the debt component may be higher or lower than our secondary market rates at the time of that calculation. As noted above, we determine the

economic terms of the securities based upon an assumed funding rate that is generally lower than our secondary market rates. In contrast, in determining the estimated value of the securities, we value the debt component using a reference interest rate that generally tracks our secondary market rates. Because the reference interest rate is generally higher than the assumed funding rate, using the reference interest rate to value the debt component generally results in a lower estimated value for the debt component, which we believe more closely approximates a market valuation of the debt component than if we had used the assumed funding rate.

WFS calculated the estimated value of the derivative component based on a proprietary derivative-pricing model, which generated a theoretical price for the derivative instruments that constitute the derivative component based on various inputs, including the derivative component factors identified in Selected Risk Considerations The Value Of The Securities Prior To Stated Maturity Will Be Affected By Numerous Factors, Some Of Which Are Related In Complex Ways. These inputs may be market-observable or may be based on assumptions made by WFS in its discretion.

The estimated value of the securities determined by WFS is subject to important limitations. See Selected Risk Considerations The Estimated Value Of The Securities Is Determined By Our Affiliate s Pricing Models, Which May Differ From Those Of Other Dealers and Our Economic Interests And Those Of Any Dealer Participating In The Offering Are Potentially Adverse To Your Interests.

PRS-3

---

**Market Linked Securities Leveraged Upside Participation and**

**Contingent Downside**

**Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

**March 7, 2022**

**Investment Description (Continued)**

*Valuation of the securities after issuance*

The estimated value of the securities is not an indication of the price, if any, at which WFS or any other person may be willing to buy the securities from you in the secondary market. The price, if any, at which WFS or any of its affiliates may purchase the securities in the secondary market will be based upon WFS's proprietary pricing models and will fluctuate over the term of the securities due to changes in market conditions and other relevant factors. However, absent changes in these market conditions and other relevant factors, except as otherwise described in the following paragraph, any secondary market price will be lower than the estimated value on the pricing date because the secondary market price will be reduced by a bid-offer spread, which may vary depending on the aggregate face amount of the securities to be purchased in the secondary market transaction, and the expected cost of unwinding any related hedging transactions. Accordingly, unless market conditions and other relevant factors change significantly in your favor, any secondary market price for the securities is likely to be less than the original offering price.

If WFS or any of its affiliates makes a secondary market in the securities at any time up to the issue date or during the 5-month period following the issue date, the secondary market price offered by WFS or any of its affiliates will be increased by an amount reflecting a portion of the costs associated with selling, structuring, hedging and issuing the securities that are included in the original offering price. Because this portion of the costs is not fully deducted upon issuance, any secondary market price offered by WFS or any of its affiliates during this period will be higher than it would be if it were based solely on WFS's proprietary pricing models less the bid-offer spread and hedging unwind costs described above. The amount of this increase in the secondary market price will decline steadily to zero over this 5-month period. If you hold the securities through an account at WFS or any of its affiliates, we expect that this increase will also be reflected in the value indicated for the securities on your brokerage account statement.

If WFS or any of its affiliates makes a secondary market in the securities, WFS expects to provide those secondary market prices to any unaffiliated broker-dealers through which the securities are held and to commercial pricing vendors. If you hold your securities through an account at a broker-dealer other than WFS or any of its affiliates, that broker-dealer may obtain market prices for the securities from WFS (directly or indirectly), but could also obtain such market prices from other sources, and may be willing to purchase the securities at any given time at a price that differs from the price at which WFS or any of its affiliates is willing to purchase the securities. As a result, if you hold your securities through an account at a broker-dealer other than WFS or any of its affiliates, the value of the securities on your brokerage account statement may be different than if you held your securities at WFS or any of its affiliates.

The securities will not be listed or displayed on any securities exchange or any automated quotation system. Although WFS and/or its affiliates may buy the securities from investors, they are not obligated to do so and are not required to make a market for the securities. There can be no assurance that a secondary market will develop.

PRS-4



---

**Market Linked Securities Leveraged Upside Participation and**

**Contingent Downside**

**Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

**March 7, 2022**

**Investor Considerations**

We have designed the securities for investors who:

seek 115% to 125% (to be determined on the pricing date) exposure to the upside performance of the Fund if the ending price is greater than the starting price;

desire repayment of the original offering price at maturity so long as the ending price is not less than the starting price by more than 20%;

understand that if the ending price is less than the starting price by more than 20%, they will be fully exposed to the decrease in the Fund from the starting price, and will lose more than 20%, and possibly all, of the original offering price per security at maturity;

are willing to forgo interest payments on the securities and dividends on shares of the Fund; and

are willing to hold the securities until maturity.

The securities are not designed for, and may not be a suitable investment for, investors who:

seek a liquid investment or are unable or unwilling to hold the securities to maturity;

are unwilling to accept the risk that the ending price of the Fund may decrease by more than 20% from the starting price;

are unwilling to purchase securities with an estimated value as of the pricing date that is lower than the original offering price and that may be as low as the lower estimated value set forth on the cover page;

seek full return of the original offering price of the securities at stated maturity;

seek current income;

are unwilling to accept the risk of exposure to companies in the health care sector of the United States equity market;

seek exposure to the Fund but are unwilling to accept the risk/return trade-offs inherent in the payment at stated maturity for the securities;

are unwilling to accept the credit risk of Wells Fargo to obtain exposure to the Fund generally, or to the exposure to the Fund that the securities provide specifically; or

prefer the lower risk of fixed income investments with comparable maturities issued by companies with comparable credit ratings.

PRS-5

**Market Linked Securities Leveraged Upside Participation and****Contingent Downside****Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due****March 7, 2022****Terms of the Securities**

|                                 |  |
|---------------------------------|--|
| <b>Market Measure:</b>          | Health Care Select Sector SPDR® Fund   |
| <b>Pricing Date:</b>            | February 28, 2017*   |
| <b>Issue Date:</b>              | March 7, 2017* (T+5)   |
| <b>Original Offering Price:</b> | \$1,000 per security. References in this pricing supplement to a <u>security</u> are to a security with a face amount of \$1,000.  |
| <b>Redemption Amount:</b>       | <p>The <u>redemption amount</u> per security will equal:</p> <p>if the ending price is greater than the starting price: \$1,000 <i>plus</i>:</p> $\$1,000 \times \frac{\text{ending price} - \text{starting price}}{\text{starting price}} \times \text{participation rate} \quad ;$ <p>if the ending price is less than or equal to the starting price, but greater than or equal to the threshold price: \$1,000; or</p> <p>if the ending price is less than the threshold price: \$1,000 <i>minus</i>:</p> $\$1,000 \times \frac{\text{starting price} - \text{ending price}}{\text{starting price}}$ <p><b>If the ending price is less than the threshold price, you will lose more than 20%, and possibly all, of the original offering price of your securities at maturity.</b></p> |
| <b>Stated Maturity</b>          | March 7, 2022*. If the calculation day is postponed, the stated maturity date will be postponed to the later of (i) March 7, 2022* and (ii) the third business day after the   |

|                                   |  |
|-----------------------------------|--|
| <b>Date:</b>                      | calculation day as postponed.  |
| <b>Starting Price:</b>            | , the fund closing price of the Fund on the pricing date.  |
| <b>Ending Price:</b>              | The <u>ending price</u> will be the fund closing price of the Fund on the calculation day.   |
| <b>Threshold Price:</b>           | , which is equal to 80% of the starting price.   |
| <b>Participation Rate:</b>        | The <u>participation rate</u> will be determined on the pricing date and will be within the range of 115% to 125%.   |
| <b>Calculation Day:</b>           | February 28, 2022.* If such day is not a trading day, the calculation day will be postponed to the next succeeding trading day. The calculation day is also subject to postponement due to the occurrence of a market disruption event.  |
| <b>Calculation Agent:</b>         | Wells Fargo Securities, LLC  |
| <b>Material Tax Consequences:</b> | For a discussion of the material U.S. federal income tax consequences of the ownership and disposition of the securities, see United States Federal Tax Considerations.  |
| <b>Agent:</b>                     | Wells Fargo Securities, LLC, a wholly owned subsidiary of Wells Fargo & Company. The agent may resell the securities to other securities dealers at the original offering price of the securities less a concession not in excess of \$25.00 per security. Such securities dealers may include Wells Fargo Advisors ( <u>WFA</u> ) (the trade name of the retail brokerage business of our affiliates, Wells Fargo Clearing Services, LLC and Wells Fargo Advisors Financial Network, LLC). In addition to the concession allowed to WFA, WFS will pay \$1.20 per security of the agent's discount to WFA as a distribution expense fee for each security sold by WFA. |
| <b>Denominations:</b>             | \$1,000 and any integral multiple of \$1,000.  |

**CUSIP:**

94986R4G3

- \* To the extent that we make any change to the expected pricing date or expected issue date, the calculation day and stated maturity date may also be changed in our discretion to ensure that the term of the securities remains the same.

PRS-6

**Market Linked Securities Leveraged Upside Participation and**

**Contingent Downside**

**Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

**March 7, 2022**

**Determining Payment at Stated Maturity**

On the stated maturity date, you will receive a cash payment per security (the redemption amount) calculated as follows:

PRS-7

**Market Linked Securities Leveraged Upside Participation and**

**Contingent Downside**

**Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

**March 7, 2022**

**Hypothetical Payout Profile**

The following profile is based on a hypothetical participation rate of 120% (the midpoint of the specified range for the participation rate) and a threshold price equal to 80% of the starting price. This graph has been prepared for purposes of illustration only. Your actual return will depend on the actual ending price, the actual participation rate and whether you hold your securities to maturity.

PRS-8

## Market Linked Securities Leveraged Upside Participation and

### Contingent Downside

#### Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due

March 7, 2022

#### Selected Risk Considerations

The securities have complex features and investing in the securities will involve risks not associated with an investment in conventional debt securities. These risks are explained in more detail in the **Risk Factors** section in the product supplement. You should reach an investment decision only after you have carefully considered with your advisors the suitability of an investment in the securities in light of your particular circumstances. The index underlying the Fund is sometimes referred to as the underlying index.

**If The Ending Price Is Less Than The Threshold Price, You Will Lose More Than 20%, And Possibly All, Of The Original Offering Price Of Your Securities At Stated Maturity.** If the ending price is less than the threshold price, the redemption amount that you receive at stated maturity will be reduced by an amount equal to the decline in the price of the Fund to the extent it is below the starting price (expressed as a percentage of the starting price). The threshold price is 80% of the starting price. For example, if the Fund has declined by 20.1% from the starting price to the ending price, you will not receive any benefit of the contingent downside feature and you will lose 20.1% of the original offering price per security. As a result, you will not receive any protection if the value of the Fund declines significantly and you may lose more than 20%, and possibly all, of the original offering price per security at stated maturity, even if the value of the Fund is greater than or equal to the starting price or the threshold price at certain times during the term of the securities.

**No Periodic Interest Will Be Paid On The Securities.** No periodic payments of interest will be made on the securities. However, if the agreed-upon tax treatment is successfully challenged by the Internal Revenue Service (the IRS), you may be required to recognize taxable income over the term of the securities. You should review the sections of this pricing supplement and the accompanying product supplement entitled **United States Federal Tax Considerations**.

**The Securities Are Subject To The Credit Risk Of Wells Fargo.** The securities are our obligations and are not, either directly or indirectly, an obligation of any third party. Any amounts payable under the securities are subject to our creditworthiness, and you will have no ability to pursue the shares of the Fund or any securities held by the Fund for payment. As a result, our actual and perceived creditworthiness may affect the value of the securities and, in the event we were to default on our obligations, you may not receive any amounts owed to you under the terms of the securities.

**The Estimated Value Of The Securities On The Pricing Date, Based On WFS's Proprietary Pricing Models, Will Be Less Than The Original Offering Price.** The original offering price of the securities includes certain costs that are borne by you. Because of these costs, the estimated value of the securities on the pricing date will be less than the original offering price. The costs included in the original



offering price relate to selling, structuring, hedging and issuing the securities, as well as to our funding considerations for debt of this type. The costs related to selling, structuring, hedging and issuing the securities include (i) the agent discount, (ii) the projected profit that our hedge counterparty (which may be one of our affiliates) expects to realize for assuming risks inherent in hedging our obligations under the securities and (iii) hedging and other costs relating to the offering of the securities. Our funding considerations are reflected in the fact that we determine the economic terms of the securities based on an assumed funding rate that is generally lower than our secondary market rates. If the costs relating to selling, structuring, hedging and issuing the securities were lower, or if the assumed funding rate we use to determine the economic terms of the securities were higher, the economic terms of the securities would be more favorable to you and the estimated value would be higher.

**The Estimated Value Of The Securities Is Determined By Our Affiliate's Pricing Models, Which May Differ From Those Of Other Dealers.** The estimated value of the securities was determined for us by WFS using its proprietary pricing models and related market inputs and assumptions referred to above under Investment Description Determining the estimated value. Certain inputs to these models may be determined by WFS in its discretion. WFS's views on these inputs may differ from other dealers' views, and WFS's estimated value of the securities may be higher, and perhaps materially higher, than the estimated value of the securities that would be determined by other dealers in the market. WFS's models and its inputs and related assumptions may prove to be wrong and therefore not an accurate reflection of the value of the securities.

**The Estimated Value Of The Securities Is Not An Indication Of The Price, If Any, At Which WFS Or Any Other Person May Be Willing To Buy The Securities From You In The Secondary Market.** The price, if any, at which WFS or any of its affiliates may purchase the securities in the secondary market will be based on WFS's proprietary pricing models and will fluctuate over the term of the securities as a result of changes in the market and other factors described in the next risk consideration. Any such secondary market price for the securities will also be reduced by a bid-offer spread, which may vary depending on the aggregate face amount of the securities to be purchased in the secondary market transaction, and the expected cost of unwinding any related hedging transactions. Unless the factors described in the next risk consideration change significantly in your favor, any such secondary market price for the securities is likely to be less than the original offering price.

PRS-9

**Market Linked Securities Leveraged Upside Participation and**

**Contingent Downside**

**Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

**March 7, 2022**

**Selected Risk Considerations (Continued)**

If WFS or any of its affiliates makes a secondary market in the securities at any time up to the issue date or during the 5-month period following the issue date, the secondary market price offered by WFS or any of its affiliates will be increased by an amount reflecting a portion of the costs associated with selling, structuring, hedging and issuing the securities that are included in the original offering price. Because this portion of the costs is not fully deducted upon issuance, any secondary market price offered by WFS or any of its affiliates during this period will be higher than it would be if it were based solely on WFS's proprietary pricing models less the bid-offer spread and hedging unwind costs described above. The amount of this increase in the secondary market price will decline steadily to zero over this 5-month period. If you hold the securities through an account at WFS or any of its affiliates, we expect that this increase will also be reflected in the value indicated for the securities on your brokerage account statement. If you hold your securities through an account at a broker-dealer other than WFS or any of its affiliates, the value of the securities on your brokerage account statement may be different than if you held your securities at WFS or any of its affiliates, as discussed above under Investment Description.

**The Value Of The Securities Prior To Stated Maturity Will Be Affected By Numerous Factors, Some Of Which Are Related In Complex Ways.** The value of the securities prior to stated maturity will be affected by the price of the Fund at that time, interest rates at that time and a number of other factors, some of which are interrelated in complex ways. The effect of any one factor may be offset or magnified by the effect of another factor. The following factors, which we refer to as the derivative component factors, are expected to affect the value of the securities: Fund performance; interest rates; volatility of the Fund; time remaining to maturity; and dividend yields on the securities included in the Fund. In addition to the derivative component factors, the value of the securities will be affected by actual or anticipated changes in our creditworthiness, as reflected in our secondary market rates. Because numerous factors are expected to affect the value of the securities, changes in the price of the Fund may not result in a comparable change in the value of the securities.

**The Securities Will Not Be Listed On Any Securities Exchange And We Do Not Expect A Trading Market For The Securities To Develop.** The securities will not be listed or displayed on any securities exchange or any automated quotation system. Although the agent and/or its affiliates may purchase the securities from holders, they are not obligated to do so and are not required to make a market for the securities. There can be no assurance that a secondary market will develop. Because we do not expect that any market makers will participate in a secondary market for the securities, the price at which you may be able to sell your securities is likely to depend on the price, if any, at which the agent is willing to buy your securities. If a secondary market does exist, it may be limited. Accordingly, there may be a limited number of buyers if you decide to sell your securities prior to stated maturity. This may affect the price you receive upon such sale. Consequently, you should be willing to hold the securities to stated maturity.

**The Amount You Receive On The Securities Will Depend Upon The Performance Of The Fund And Therefore The Securities Are Subject To The Following Risks, As Discussed In More Detail In The Product Supplement:**

*Your Return On The Securities Could Be Less Than If You Owned The Shares Of The Fund.* Your return on the securities will not reflect the return you would realize if you actually owned the shares of the Fund because, among other reasons, the redemption amount will be determined by reference only to the closing price of a share of the Fund without taking into consideration the value of dividends and other distributions paid on such share.

*Historical Prices Of The Fund Or The Securities Included In The Fund Should Not Be Taken As An Indication Of The Future Performance Of The Fund During The Term Of The Securities.*

*Changes That Affect The Fund Or The Underlying Index May Adversely Affect The Value Of The Securities And The Amount You Will Receive At Stated Maturity.*

*We Cannot Control Actions By Any Of The Unaffiliated Companies Whose Securities Are Included In The Fund Or The Underlying Index.*

*We And Our Affiliates Have No Affiliation With The Sponsor Of The Fund Or The Sponsor Of The Underlying Index And Have Not Independently Verified Their Public Disclosure Of Information.*

**An Investment In The Securities Is Subject To Risks Associated With Investing In Stocks In The Health Care Sector.** The stocks included in the Health Care Select Sector Index and that are generally tracked by the Fund are stocks of companies whose primary business is directly associated with the health care sector. Because the value of the securities is linked to the performance of the Fund, an investment in the securities exposes investors to risks associated with investments in the stocks of companies in the health care sector. Companies in the health care sector are subject to extensive government regulation and their profitability can be significantly affected by restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure (including price discounting), limited product lines and an increased emphasis on the delivery of healthcare through outpatient services. Companies in the health care sector are heavily dependent on obtaining and defending patents, which may be time consuming and costly, and the expiration of patents may also adversely affect the profitability of these

---

**Market Linked Securities Leveraged Upside Participation and**

**Contingent Downside**

**Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

**March 7, 2022**

**Selected Risk Considerations (Continued)**

companies. Health care companies are also subject to extensive litigation based on product liability and similar claims. In addition, their products can become obsolete due to industry innovation, changes in technologies or other market developments. Many new products in the health care sector require significant research and development and may be subject to regulatory approvals, all of which may be time consuming and costly with no guarantee that any product will come to market. The value of the securities may be subject to greater volatility and be more adversely affected by a single economic, political or regulatory occurrence affecting the health care sector than a different investment linked to a more broadly diversified group of issuers. All of these factors could have an adverse effect on the price of the Fund and, therefore, on the value of the securities.

**The Fund May Not Be Representative Of An Investment In The Health Care Sector.** The Fund does not represent a direct investment in the health care sector. The Fund consists of securities of companies whose primary lines of business are directly associated with the health care sector. As a result, the fund closing price of the Fund will be influenced by a variety of economic, financial and other factors affecting those companies, some of which may be unrelated to the market and other conditions applicable to the U.S. health care sector. As a result, the Fund may not perfectly correlate with the performance in the health care sector and the fund closing price of the Fund could decrease even if the performance of the health care sector as a whole increases.

**An Investment Linked To The Shares Of The Fund Is Different From An Investment Linked To The Underlying Index.** The performance of the shares of the Fund may not exactly replicate the performance of the underlying index because the Fund may not invest in all of the securities included in the underlying index and because the Fund will reflect transaction costs and fees that are not included in the calculation of the underlying index. The Fund may also hold securities or derivative financial instruments not included in the underlying index. It is also possible that the Fund may not fully replicate the performance of the underlying index due to the temporary unavailability of certain securities in the secondary market or due to other extraordinary circumstances. In addition, because the shares of the Fund are traded on a securities exchange and are subject to market supply and investor demand, the value of a share of the Fund may differ from the net asset value per share of the Fund. As a result, the performance of the Fund may not correlate perfectly with the performance of the underlying index, and the return on the securities based on the performance of the Fund will not be the same as the return on securities based on the performance of the underlying index.

**You Will Not Have Any Shareholder Rights With Respect To The Shares Of The Fund.**

**Anti-dilution Adjustments Relating To The Shares Of The Fund Do Not Address Every Event That Could Affect Such Shares.**

**The Stated Maturity Date May Be Postponed If The Calculation Day Is Postponed.** The calculation day will be postponed if the originally scheduled calculation day is not a trading day or if the calculation agent determines that a market disruption event has occurred or is continuing on the calculation day. If such a postponement occurs, the stated maturity date will be the later of (i) the initial stated maturity date and (ii) three business days after the postponed calculation day.

**Our Economic Interests And Those Of Any Dealer Participating In The Offering Are Potentially Adverse To Your Interests.** You should be aware of the following ways in which our economic interests and those of any dealer participating in the distribution of the securities, which we refer to as a participating dealer, are potentially adverse to your interests as an investor in the securities. In engaging in certain of the activities described below, our affiliates or any participating dealer or its affiliates may take actions that may adversely affect the value of and your return on the securities, and in so doing they will have no obligation to consider your interests as an investor in the securities. Our affiliates or any participating dealer or its affiliates may realize a profit from these activities even if investors do not receive a favorable investment return on the securities.

*The calculation agent is our affiliate and may be required to make discretionary judgments that affect the return you receive on the securities.* WFS, which is our affiliate, will be the calculation agent for the securities. As calculation agent, WFS will determine the ending price of the Fund and may be required to make other determinations that affect the return you receive on the securities at maturity. In making these determinations, the calculation agent may be required to make discretionary judgments, including determining whether a market disruption event has occurred on the scheduled calculation day, which may result in postponement of the calculation day; determining the ending price of the Fund if the calculation day is postponed to the last day to which it may be postponed and a market disruption event occurs on that day; adjusting the adjustment factor and other terms of the securities in certain circumstances; if the Fund undergoes a liquidation event, selecting a successor fund or, if no successor fund is available, determining the ending price of the Fund; and determining whether to adjust the ending price of the Fund on the calculation day in the event of certain changes in or modifications to the Fund or the underlying index. In making these discretionary judgments, the fact that WFS is our affiliate may cause it to have economic interests that are adverse to your interests as an investor in the securities, and WFS's determinations as calculation agent may adversely affect your return on the securities.

---

**Market Linked Securities Leveraged Upside Participation and**

**Contingent Downside**

**Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

**March 7, 2022**

**Selected Risk Considerations (Continued)**

***The estimated value of the securities was calculated by our affiliate and is therefore not an independent third-party valuation.*** WFS calculated the estimated value of the securities set forth on the cover page of this pricing supplement, which involved discretionary judgments by WFS, as described under Selected Risk Considerations The Estimated Value Of The Securities Is Determined By Our Affiliate's Pricing Models, Which May Differ From Those Of Other Dealers above. Accordingly, the estimated value of the securities set forth on the cover page of this pricing supplement is not an independent third-party valuation.

***Research reports by our affiliates or any participating dealer or its affiliates may be inconsistent with an investment in the securities and may adversely affect the price of the Fund.*** Our affiliates or any participating dealer in the offering of the securities or its affiliates may, at present or in the future, publish research reports on the Fund or the underlying index or the companies whose securities are included in the Fund or the underlying index. This research is modified from time to time without notice and may, at present or in the future, express opinions or provide recommendations that are inconsistent with purchasing or holding the securities. Any research reports on the Fund or the underlying index or the companies whose securities are included in the Fund or the underlying index could adversely affect the price of the Fund and, therefore, adversely affect the value of and your return on the securities. You are encouraged to derive information concerning the Fund from multiple sources and should not rely on the views expressed by us or our affiliates or any participating dealer or its affiliates. In addition, any research reports on the Fund or the underlying index or the companies whose securities are included in the Fund or the underlying index published on or prior to the pricing date could result in an increase in the price of the Fund on the pricing date, which would adversely affect investors in the securities by increasing the price at which the Fund must close on the calculation day in order for investors in the securities to receive a favorable return.

***Business activities of our affiliates or any participating dealer or its affiliates with the companies whose securities are included in the Fund may adversely affect the price of the Fund.*** Our affiliates or any participating dealer or its affiliates may, at present or in the future, engage in business with the companies whose securities are included in the Fund or the underlying index, including making loans to those companies (including exercising creditors' remedies with respect to such loans), making equity investments in those companies or providing investment banking, asset management or other advisory services to those companies. These business activities could adversely affect the price of the Fund and, therefore, adversely affect the value of and your return on the securities. In addition, in the course of these business activities, our affiliates or any participating dealer or its affiliates may acquire non-public information about one or more of the companies whose securities are included in the Fund or the underlying index. If our affiliates or any participating dealer or its affiliates do acquire such non-public information, we and they are not obligated to disclose such non-public

information to you.

***Hedging activities by our affiliates or any participating dealer or its affiliates may adversely affect the price of the Fund.*** We expect to hedge our obligations under the securities through one or more hedge counterparties, which may include our affiliates or any participating dealer or its affiliates. Pursuant to such hedging activities, our hedge counterparties may acquire shares of the Fund, securities included in the Fund or the underlying index or listed or over-the-counter derivative or synthetic instruments related to the Fund or such securities. Depending on, among other things, future market conditions, the aggregate amount and the composition of such positions are likely to vary over time. To the extent that our hedge counterparties have a long hedge position in shares of the Fund or any of the securities included in the Fund or the underlying index, or derivative or synthetic instruments related to the Fund or such securities, they may liquidate a portion of such holdings at or about the time of the calculation day or at or about the time of a change in the securities included in the Fund or the underlying index. These hedging activities could potentially adversely affect the price of the shares of the Fund and, therefore, adversely affect the value of and your return on the securities.

***Trading activities by our affiliates or any participating dealer or its affiliates may adversely affect the price of the Fund.*** Our affiliates or any participating dealer or its affiliates may engage in trading in the shares of the Fund or the securities included in the Fund or the underlying index and other instruments relating to the Fund or such securities on a regular basis as part of their general broker-dealer and other businesses. Any of these trading activities could potentially adversely affect the price of the shares of the Fund and, therefore, adversely affect the value of and your return on the securities.

***A participating dealer or its affiliates may realize hedging profits projected by its proprietary pricing models in addition to any selling concession and/or distribution expense fee, creating a further incentive for the participating dealer to sell the securities to you.*** If any participating dealer or any of its affiliates conducts hedging activities for us in connection with the securities, that participating dealer or its affiliates will expect to realize a projected profit from such hedging activities and this projected profit will be in addition to the concession and/or distribution expense fee that the participating dealer realizes for the sale of the securities to you. This additional projected profit may create a further incentive for the participating dealer to sell the securities to you.

PRS-12

---

**Market Linked Securities Leveraged Upside Participation and**

**Contingent Downside**

**Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

**March 7, 2022**

**Selected Risk Considerations (Continued)**

**The U.S. Federal Tax Consequences Of An Investment In The Securities Are Unclear.** There is no direct legal authority regarding the proper U.S. federal tax treatment of the securities, and we do not plan to request a ruling from the IRS. Consequently, significant aspects of the tax treatment of the securities are uncertain, and the IRS or a court might not agree with the treatment of the securities as prepaid derivative contracts that are open transactions for U.S. federal income tax purposes. If the IRS were successful in asserting an alternative treatment of the securities, the tax consequences of ownership and disposition of the securities might be materially and adversely affected. Even if the treatment of the securities as prepaid derivative contracts that are open transactions is respected, a security may be treated as a constructive ownership transaction, with potentially adverse consequences described below under United States Federal Tax Considerations.

Furthermore, Section 871(m) of the Internal Revenue Code of 1986, as amended (the Code), imposes a withholding tax of up to 30% on dividend equivalents paid or deemed paid to non-U.S. investors in respect of certain financial instruments linked to U.S. equities. In light of IRS regulations providing a general exemption for financial instruments issued in 2017 that do not have a delta of one, as of the date of this preliminary pricing supplement the securities should not be subject to withholding under Section 871(m). However, information about the application of Section 871(m) to the securities will be updated in the final pricing supplement. Moreover, the IRS could challenge a conclusion that the securities should not be subject to withholding under Section 871(m). If withholding applies to the securities, we will not be required to pay any additional amounts with respect to amounts withheld.

In addition, in 2007 the U.S. Treasury Department and the IRS released a notice requesting comments on various issues regarding the U.S. federal income tax treatment of prepaid forward contracts and similar instruments. Any Treasury regulations or other guidance promulgated after consideration of these issues could materially and adversely affect the tax consequences of an investment in the securities, including the character and timing of income or loss and the degree, if any, to which income realized by non-U.S. persons should be subject to withholding tax, possibly with retroactive effect. You should read carefully the sections of this pricing supplement and the accompanying product supplement entitled United States Federal Tax Considerations. You should also consult your tax adviser regarding the U.S. federal tax consequences of an investment in the securities, as well as tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.



**Market Linked Securities Leveraged Upside Participation and****Contingent Downside****Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due****March 7, 2022****Hypothetical Returns**

The following table illustrates, for a hypothetical participation rate of 120.00% (the midpoint of the specified range for the participation rate) and a range of hypothetical ending prices of the Fund:

the hypothetical percentage change from the hypothetical starting price to the hypothetical ending price;

the hypothetical redemption amount payable at stated maturity per security;

the hypothetical total pre-tax rate of return; and

the hypothetical pre-tax annualized rate of return.

| <b>Hypothetical</b>              | <b>Hypothetical</b>              | <b>Hypothetical</b>      | <b>Hypothetical</b>   | <b>Hypothetical</b>                 |
|----------------------------------|----------------------------------|--------------------------|-----------------------|-------------------------------------|
| <b>ending price</b>              | <b>percentage change</b>         | <b>redemption amount</b> | <b>pre-tax total</b>  | <b>pre-tax</b>                      |
| <b>from the hypothetical</b>     | <b>from the hypothetical</b>     | <b>payable at</b>        | <b>pre-tax total</b>  | <b>annualized</b>                   |
| <b>starting price to the</b>     | <b>starting price to the</b>     | <b>stated maturity</b>   | <b>pre-tax total</b>  | <b>annualized</b>                   |
| <b>hypothetical ending price</b> | <b>hypothetical ending price</b> | <b>per security</b>      | <b>rate of return</b> | <b>rate of return<sup>(1)</sup></b> |
| \$124.48                         | 75.00%                           | \$1,900.00               | 90.00%                | 13.25%                              |
| \$106.70                         | 50.00%                           | \$1,600.00               | 60.00%                | 9.62%                               |
| \$99.58                          | 40.00%                           | \$1,480.00               | 48.00%                | 7.99%                               |
| \$92.47                          | 30.00%                           | \$1,360.00               | 36.00%                | 6.24%                               |
| \$85.36                          | 20.00%                           | \$1,240.00               | 24.00%                | 4.35%                               |
| \$78.24                          | 10.00%                           | \$1,120.00               | 12.00%                | 2.28%                               |
| \$74.69                          | 5.00%                            | \$1,060.00               | 6.00%                 | 1.17%                               |
| \$71.13 <sup>(2)</sup>           | 0.00%                            | \$1,000.00               | 0.00%                 | 0.00%                               |
| \$64.02                          | -10.00%                          | \$1,000.00               | 0.00%                 | 0.00%                               |
| \$60.46                          | -15.00%                          | \$1,000.00               | 0.00%                 | 0.00%                               |
| \$56.904                         | -20.00%                          | \$1,000.00               | 0.00%                 | 0.00%                               |
| \$56.19                          | -21.00%                          | \$790.00                 | -21.00%               | -4.66%                              |
| \$49.79                          | -30.00%                          | \$700.00                 | -30.00%               | -7.00%                              |

Edgar Filing: WELLS FARGO & COMPANY/MN - Form 424B2

|         |         |          |         |         |
|---------|---------|----------|---------|---------|
| \$35.57 | -50.00% | \$500.00 | -50.00% | -13.39% |
| \$17.78 | -75.00% | \$250.00 | -75.00% | -25.88% |

(1) The annualized rates of return are calculated on a semi-annual bond equivalent basis with compounding.

(2) The hypothetical starting price. The actual starting price will be determined on the pricing date.

The above figures are for purposes of illustration only and may have been rounded for ease of analysis. The actual amount you receive at stated maturity and the resulting pre-tax rate of return will depend on the actual starting price, ending price and participation rate.

PRS-14

**Market Linked Securities Leveraged Upside Participation and****Contingent Downside****Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due****March 7, 2022****Hypothetical Payments at Stated Maturity**

Set forth below are three examples of payment at stated maturity calculations, reflecting a hypothetical participation rate of 120% (the midpoint of the specified range for the participation rate) and assuming hypothetical starting prices and ending prices as indicated in the examples. These examples are for purposes of illustration only and the values used in the examples may have been rounded for ease of analysis.

**Example 1. Redemption amount is greater than the original offering price:**

Hypothetical starting price: \$71.13

Hypothetical ending price: \$78.24

Since the hypothetical ending price is greater than the hypothetical starting price, the redemption amount would equal:

$$\$1,000 + \$1,000 \times \frac{\$78.24 - \$71.13}{\$71.13} \times 120\% = \$1,120.00$$

On the stated maturity date you would receive \$1,120.00 per security.

**Example 2. Redemption amount is equal to the original offering price:**

Hypothetical starting price: \$71.13

Hypothetical ending price: \$64.02

Hypothetical threshold price: \$56.904, which is 80% of the hypothetical starting price

Since the hypothetical ending price is less than the hypothetical starting price, but not by more than 20%, you would not lose any of the original offering price of your securities.

On the stated maturity date you would receive \$1,000.00 per security.

**Example 3. Redemption amount is less than the original offering price:**

Hypothetical starting price: \$71.13

Hypothetical ending price: \$35.57

Hypothetical threshold price: \$56.904, which is 80% of the hypothetical starting price

Since the hypothetical ending price is less than the hypothetical starting price by more than 20%, you would lose a portion of the original offering price of your securities and receive the redemption amount equal to:

$$\$1,000 \quad \$1,000 \times \frac{\$71.13 - \$35.57}{\$71.13} = \$500.00$$

On the stated maturity date you would receive \$500.00 per security.

To the extent that the starting price, ending price and participation rate differ from the values assumed above, the results indicated above would be different.

PRS-15

---

**Market Linked Securities Leveraged Upside Participation and**

**Contingent Downside**

**Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

**March 7, 2022**

**The Health Care Select Sector SPDR Fund**

The Fund is issued by The Select Sector SPDR Trust, a registered open-end management investment company. The Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the Health Care Select Sector Index. For a description of the Health Care Select Sector Index, please see *The Health Care Select Sector Index* below. Information provided to or filed with the Securities and Exchange Commission (the SEC) by the Fund under the Securities Act of 1933, as amended, and the Investment Company Act of 1940, as amended, can be located by reference to SEC file numbers 333-57791 and 811-08837 and can be inspected and copied at the public reference facilities maintained by the SEC or through the SEC's website at [www.sec.gov](http://www.sec.gov). In addition, information may be obtained from other sources including, but not limited to, press releases, newspaper articles and other publicly disseminated documents. None of such publicly available information is incorporated by reference into this pricing supplement. The Fund is listed on the NYSE Arca, Inc. under the ticker symbol XLV.

This pricing supplement relates only to the securities offered hereby and does not relate to the Fund. We have derived all disclosures contained in this pricing supplement regarding the Fund from the publicly available documents described in the preceding paragraph. In connection with the offering of the securities, neither we nor the agent has participated in the preparation of such documents or made any due diligence inquiry with respect to the Fund. Neither we nor the agent has independently verified the accuracy or completeness of any information with respect to the Fund in connection with the offer and sale of the securities. Furthermore, we cannot give any assurance that all events occurring prior to the date hereof (including events that would affect the accuracy or completeness of the publicly available documents described in the preceding paragraph) that would affect the trading price of the Fund (and therefore the price of the Fund at the time we price the securities) have been publicly disclosed. Subsequent disclosure of any such events or the disclosure of or failure to disclose material future events concerning the Fund could affect the maturity payment amount and therefore the trading prices of the securities.

We and/or our affiliates may presently or from time to time engage in business with the Fund. In the course of such business, we and/or our affiliates may acquire non-public information with respect to the Fund, and neither we nor any of our affiliates undertakes to disclose any such information to you. In addition, one or more of our affiliates may publish research reports with respect to the Fund. The statements in the preceding two sentences are not intended to affect the rights of investors in the securities under the securities laws.

***The Health Care Select Sector Index***

The Health Care Select Sector Index is a modified market capitalization-based index, intended to provide investors with a way to track the movements of certain public companies that represent the health care sector of the S&P 500® Index. The Health Care Select Sector Index includes companies in the following industries: health care equipment and supplies, health care providers and services, health care technology, biotechnology, pharmaceuticals and life sciences tools and services. The Health Care Select Sector Index is one of the eleven Select Sector sub-indices of the S&P 500 Index, each of which is referred to as a *Select Sector Index* in the accompanying market measure supplement. See *Description of Equity Indices The Select Sector Indices* in the accompanying market measure supplement for additional information about the Health Care Select Sector Index.

PRS-16

**Market Linked Securities Leveraged Upside Participation and**

**Contingent Downside**

**Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

**March 7, 2022**

**The Health Care Select Sector SPDR Fund (Continued)**

**Historical Information**

We obtained the closing prices listed below from Bloomberg Financial Markets, without independent verification.

The following graph sets forth daily closing prices of the Fund for the period from January 1, 2007 to February 1, 2017. The closing price on February 1, 2017 was \$71.13. The historical performance of the Fund should not be taken as an indication of the future performance of the Fund during the term of the securities.

PRS-17

**Market Linked Securities Leveraged Upside Participation and****Contingent Downside****Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due****March 7, 2022****The Health Care Select Sector SPDR Fund (Continued)**

The following table sets forth the high and low closing prices, as well as end-of-period closing prices, of the Fund for each quarter in the period from January 1, 2007 through December 31, 2016 and for the period from January 1, 2017 to February 1, 2017.

|                | High     | Low      | Last     |
|----------------|----------|----------|----------|
| 2007           |          |          |          |
| First Quarter  | \$ 34.85 | \$ 33.09 | \$ 33.67 |
| Second Quarter | \$ 36.78 | \$ 33.83 | \$ 35.23 |
| Third Quarter  | \$ 35.98 | \$ 33.60 | \$ 35.39 |
| Fourth Quarter | \$ 36.74 | \$ 34.79 | \$ 35.21 |
| 2008           |          |          |          |
| First Quarter  | \$ 36.44 | \$ 30.64 | \$ 30.93 |
| Second Quarter | \$ 32.25 | \$ 29.92 | \$ 30.56 |
| Third Quarter  | \$ 33.61 | \$ 29.93 | \$ 30.45 |
| Fourth Quarter | \$ 30.44 | \$ 23.56 | \$ 26.55 |
| 2009           |          |          |          |
| First Quarter  | \$ 27.46 | \$ 21.88 | \$ 24.21 |
| Second Quarter | \$ 26.53 | \$ 23.77 | \$ 26.31 |
| Third Quarter  | \$ 29.04 | \$ 25.64 | \$ 28.67 |
| Fourth Quarter | \$ 31.64 | \$ 28.05 | \$ 31.08 |
| 2010           |          |          |          |
| First Quarter  | \$ 33.00 | \$ 30.68 | \$ 32.08 |
| Second Quarter | \$ 32.31 | \$ 28.17 | \$ 28.17 |
| Third Quarter  | \$ 30.70 | \$ 27.96 | \$ 30.48 |
| Fourth Quarter | \$ 31.77 | \$ 30.19 | \$ 31.50 |
| 2011           |          |          |          |
| First Quarter  | \$ 33.18 | \$ 31.61 | \$ 33.13 |
| Second Quarter | \$ 36.42 | \$ 33.28 | \$ 35.52 |
| Third Quarter  | \$ 35.95 | \$ 29.99 | \$ 31.72 |
| Fourth Quarter | \$ 34.88 | \$ 30.70 | \$ 34.69 |
| 2012           |          |          |          |
| First Quarter  | \$ 37.59 | \$ 34.97 | \$ 37.59 |
| Second Quarter | \$ 38.00 | \$ 35.53 | \$ 38.00 |
| Third Quarter  | \$ 40.31 | \$ 37.40 | \$ 40.11 |
| Fourth Quarter | \$ 41.35 | \$ 38.64 | \$ 39.95 |



|                                     |          |          |          |
|-------------------------------------|----------|----------|----------|
| 2013                                |          |          |          |
| First Quarter                       | \$ 45.95 | \$ 40.65 | \$ 45.95 |
| Second Quarter                      | \$ 49.62 | \$ 46.07 | \$ 47.61 |
| Third Quarter                       | \$ 52.04 | \$ 47.57 | \$ 50.57 |
| Fourth Quarter                      | \$ 55.47 | \$ 49.87 | \$ 55.44 |
| 2014                                |          |          |          |
| First Quarter                       | \$ 60.12 | \$ 54.86 | \$ 58.49 |
| Second Quarter                      | \$ 61.23 | \$ 55.71 | \$ 60.83 |
| Third Quarter                       | \$ 65.27 | \$ 59.82 | \$ 63.91 |
| Fourth Quarter                      | \$ 71.04 | \$ 60.21 | \$ 68.38 |
| 2015                                |          |          |          |
| First Quarter                       | \$ 74.88 | \$ 68.02 | \$ 72.50 |
| Second Quarter                      | \$ 76.45 | \$ 71.68 | \$ 74.39 |
| Third Quarter                       | \$ 77.22 | \$ 64.29 | \$ 66.23 |
| Fourth Quarter                      | \$ 72.99 | \$ 66.86 | \$ 72.05 |
| 2016                                |          |          |          |
| First Quarter                       | \$ 71.07 | \$ 63.52 | \$ 67.78 |
| Second Quarter                      | \$ 72.65 | \$ 68.32 | \$ 71.72 |
| Third Quarter                       | \$ 75.61 | \$ 71.38 | \$ 72.11 |
| Fourth Quarter                      | \$ 72.20 | \$ 66.02 | \$ 68.94 |
| 2017                                |          |          |          |
| January 1, 2017 to February 1, 2017 | \$ 71.50 | \$ 69.07 | \$ 71.13 |

PRS-18

---

**Market Linked Securities Leveraged Upside Participation and**

**Contingent Downside**

**Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

**March 7, 2022**

**United States Federal Tax Considerations**

You should read carefully the discussion under **United States Federal Tax Considerations** in the accompanying product supplement and **Selected Risk Considerations** in this pricing supplement.

In the opinion of our counsel, Davis Polk & Wardwell LLP, which is based on current market conditions, a security should be treated as a prepaid derivative contract that is an **open transaction** for U.S. federal income tax purposes. By purchasing a security, you agree (in the absence of an administrative determination or judicial ruling to the contrary) to this treatment. There is uncertainty regarding this treatment, and the IRS or a court might not agree with it.

Assuming this treatment of the securities is respected and subject to the discussion in **United States Federal Tax Considerations** in the accompanying product supplement, the following U.S. federal income tax consequences should result under current law:

You should not recognize taxable income over the term of the securities prior to maturity, other than pursuant to a sale or exchange.

Upon a sale or exchange of a security (including retirement at maturity), you should recognize gain or loss equal to the difference between the amount realized and your tax basis in the security. Subject to the discussion below concerning the potential application of the **constructive ownership** rules under Section 1260 of the Code, any gain or loss recognized upon a sale, exchange or retirement of a security should be long-term capital gain or loss if you held the security for more than one year.

Even if the treatment of the securities as prepaid derivative contracts that are **open transactions** is respected, your purchase of a security may be treated as entry into a **constructive ownership** transaction, within the meaning of Section 1260 of the Code, with respect to the shares of the Fund. In that case, all or a portion of any long-term capital gain you would otherwise recognize in respect of your securities would be recharacterized as ordinary income to the extent such gain exceeded the **net underlying long-term capital gain**. Although the matter is unclear, the **net underlying long-term capital gain** may equal the amount of long-term capital gain you would have realized if on the issue date you had purchased shares of the Fund with a value equal to the amount you paid to acquire your securities and subsequently sold those shares for their fair market value at the time your securities are sold, exchanged or retired (which would reflect the percentage increase, without regard to the participation rate, in the value of the shares of the Fund over the term of the securities). Alternatively, the **net underlying long-term capital gain** could be calculated using a number of shares of the Fund that reflects the participation rate used to calculate the payment that you will receive on your securities. Any long-term capital gain recharacterized as ordinary income under Section 1260 would be treated as accruing at a constant rate over the period you held your securities, and you would be subject to an interest charge in respect of the deemed tax liability on the income treated as accruing in prior tax years. Due to the lack of governing authority under Section 1260, our counsel is not able to opine as to whether or how Section 1260 applies to the securities. You should read the section entitled **United States Federal Tax Considerations Tax**

Consequences to U.S. Holders Potential Application of Section 1260 of the Code in the accompanying product supplement for additional information and consult your tax adviser regarding the potential application of the constructive ownership rule.

Subject to the discussion below, if you are a non-U.S. holder (as defined in the accompanying product supplement) of the securities, you generally should not be subject to U.S. federal withholding or income tax in respect of any amount paid to you with respect to the securities, provided that (i) income in respect of the securities is not effectively connected with your conduct of a trade or business in the United States, and (ii) you comply with the applicable certification requirements.

As discussed in the section of the accompanying product supplement entitled United States Federal Tax Considerations FATCA Legislation, withholding under legislation commonly referred to as FATCA might (if the securities were recharacterized as debt instruments) apply to amounts treated as interest or dividend equivalents paid with respect to the securities. However, under an IRS notice, withholding under FATCA will apply to the payment of gross proceeds (other than any amount treated as interest) only with respect to a disposition of the securities after December 31, 2018. You should consult your tax adviser regarding the potential application of FATCA to the securities.

In 2007, the U.S. Treasury Department and the IRS released a notice requesting comments on the U.S. federal income tax treatment of prepaid forward contracts and similar instruments. The notice focuses in particular on whether to require holders of these instruments to accrue income over the term of their investment. It also asks for comments on a number of related topics, including the character of income or loss with respect to these instruments; whether short-term instruments should be subject to any such accrual regime; the relevance of factors such as the exchange-traded status of the instruments and the nature of the underlying property to which the instruments are linked; the degree, if any, to which income (including any mandated accruals) realized by non-U.S. investors should be subject to withholding tax; and whether these instruments are or should be subject to the constructive ownership regime described above. While the notice requests comments on appropriate transition rules and effective dates, any Treasury regulations or other guidance promulgated after consideration of these issues could materially and adversely affect the tax

**Market Linked Securities Leveraged Upside Participation and**

**Contingent Downside**

**Principal at Risk Securities Linked to the Health Care Select Sector SPDR® Fund due**

**March 7, 2022**

**United States Federal Tax Considerations (Continued)**

consequences of an investment in the securities, including the character and timing of income or loss and the degree, if any, to which income realized by non-U.S. persons should be subject to withholding tax, possibly with retroactive effect.

*Possible Withholding Under Section 871(m) of the Code.* Section 871(m) of the Code and Treasury regulations promulgated thereunder ( Section 871(m) ) generally impose a 30% withholding tax on dividend equivalents paid or deemed paid to non-U.S. holders with respect to certain financial instruments linked to U.S. equities ( U.S. Underlying Equities ). Section 871(m) generally applies to instruments that substantially replicate the economic performance of one or more U.S. Underlying Equities, as determined based on tests set forth in the applicable Treasury regulations ( a Specified Security ). However, the regulations exempt financial instruments issued in 2017 that do not have a  $\Delta$  of one. Based on the terms of the securities and representations provided by us, our counsel is of the opinion that the securities should not be treated as transactions that have a  $\Delta$  of one within the meaning of the regulations with respect to any U.S. Underlying Equity and, therefore, should not be Specified Securities subject to withholding tax under Section 871(m).

A determination that the securities are not subject to Section 871(m) is not binding on the IRS, and the IRS may disagree with this treatment. Moreover, Section 871(m) is complex and its application may depend on your particular circumstances. For example, if you enter into other transactions relating to the underlier, you could be subject to withholding tax or income tax liability under Section 871(m) even if the securities are not Specified Securities subject to Section 871(m) as a general matter. You should consult your tax adviser regarding the potential application of Section 871(m) to the securities.

This information is indicative and will be supplemented and superseded in the final pricing supplement or as may otherwise be updated by us in writing from time to time. Non-U.S. holders should be warned that Section 871(m) may apply to the securities based on circumstances as of the pricing date for the securities and, therefore, it is possible that the securities will be subject to withholding tax under Section 871(m).

If withholding tax applies to the securities, we will not be required to pay any additional amounts with respect to amounts so withheld.

**You should read the section entitled United States Federal Tax Considerations in the accompanying product supplement. The preceding discussion, when read in combination with that section, constitutes the full opinion of Davis Polk & Wardwell LLP regarding the material U.S. federal tax consequences of owning and disposing of the securities.**

**You should consult your tax adviser regarding all aspects of the U.S. federal income and estate tax consequences of an investment in the securities and any tax consequences arising under the laws of any state,**

**local or non-U.S. taxing jurisdiction.**

PRS-20